Autolus Therapeutics Provides Business Updates and 2025 Overview
Autolus Therapeutics plc - American Depositary Shares (AUTL)
Last autolus therapeutics plc - american depositary shares earnings: 11/7 07:06 am
Check Earnings Report
US:NASDAQ Investor Relations:
autolus.com/investor-relations
Company Research
Source: GlobeNewswire
- Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th - National Comprehensive Cancer Network® adds AUCATZYL® to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies to patients, today announces business updates and an overview of 2025 milestones. "We enter 2025 with good momentum following the recent U.S. Food and Drug Administration (FDA) approval of AUCATZYL® (obecabtagene autoleucel, or “obe-cel”) and publication of the FELIX trial data in the New England Journal of Medicine. In addition, the inclusion of AUCATZYL® in the NCCN Guidelines, noting the lack of REMS
Show less
Read more
Impact Snapshot
Event Time:
AUTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUTL alerts
High impacting Autolus Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AUTL
News
- Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030PR Newswire
- Autolus Therapeutics (NASDAQ:AUTL) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $10.00 price target on the stock.MarketBeat
- Autolus Therapeutics Presents Updated Clinical Data from the CARLYSLE Trial in Patients with Severe Refractory Systemic Lupus Erythematosus at the American Society of Hematology (ASH) Annual Meeting 2025GlobeNewswire
- Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025GlobeNewswire
- Autolus Therapeutics Appoints Ryan Richardson to Board of Directors [Yahoo! Finance]Yahoo! Finance
AUTL
Earnings
- 11/12/25 - Miss
AUTL
Sec Filings
- 12/3/25 - Form SCHEDULE
- 12/2/25 - Form 424B3
- 12/2/25 - Form 8-K
- AUTL's page on the SEC website